PROREIT ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2024 RESULTS
- Nektar Therapeutics reported a fourth-quarter revenue of $29.2 million for 2024, up from $23.9 million in the previous year, with total operating costs decreasing significantly to $14.8 million from $57.4 million.
- Nektar's cash and marketable securities totaled $269.1 million on December 31, 2024, down from $329.4 million a year earlier.
- Howard W. Robin, President and CEO of Nektar, stated that they are on track to report topline data for rezpegaldesleukin in 2025.
- Nektar's net loss for 2024 was $119.0 million, a decrease from a loss of $276.1 million in the previous year.
Insights by Ground AI
Does this summary seem wrong?
85 Articles
85 Articles
All
Left
17
Center
25
Right
4
Coverage Details
Total News Sources85
Leaning Left17Leaning Right4Center25Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 37%
C 54%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage